Ghali Jalal K, Hamad Bashar, Yasothan Uma, Kirkpatrick Peter
Harper University Hospital, 3990 John R Street, 9 Webber Core, Detroit, MI 48201, USA.
Nat Rev Drug Discov. 2009 Aug;8(8):611-2. doi: 10.1038/nrd2946.
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
2009年5月，选择性血管加压素V(2)受体拮抗剂托伐普坦（Samsca；大冢制药）获美国食品药品监督管理局批准，用于治疗具有临床意义的高容量性和等容量性低钠血症。
